[Federal Register Volume 81, Number 98 (Friday, May 20, 2016)]
[Notices]
[Page 31959]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-11939]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-392]


Manufacturer of Controlled Substances Registration: Pharmacore, 
Inc.

ACTION: Notice of registration.

-----------------------------------------------------------------------

SUMMARY: Pharmacore, Inc. applied to be registered as a manufacturer of 
certain basic classes of controlled substances. The Drug Enforcement 
Administration (DEA) grants Pharmacore, Inc. registration as a 
manufacturer of those controlled substances.

SUPPLEMENTARY INFORMATION:  By notice dated January 27, 2016, and 
published in the Federal Register on February 4, 2016, 81 FR 6044, 
Pharmacore, Inc., 4180 Mendenhall Oaks Parkway, High Point, North 
Carolina 27265 applied to be registered as a manufacturer of certain 
basic classes of controlled substances. No comments or objections were 
submitted for this notice.
    The DEA has considered the factors in 21 U.S.C. 823(a) and 
determined that the registration of Pharmacore, Inc. to manufacture the 
basic classes of controlled substances is consistent with the public 
interest and with United States obligations under international 
treaties, conventions, or protocols in effect on May 1, 1971. The DEA 
investigated the company's maintenance of effective controls against 
diversion by inspecting and testing the company's physical security 
systems, verifying the company's compliance with state and local laws, 
and reviewing the company's background and history.
    Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 
CFR 1301.33, the above-named company is granted registration as a bulk 
manufacturer of the following basic classes of controlled substances:

------------------------------------------------------------------------
            Controlled substance                       Schedule
------------------------------------------------------------------------
Oxymorphone (9652)..........................  II
Noroxymorphone (9668).......................  II
------------------------------------------------------------------------

    The company plans to manufacture the listed controlled substances 
as active pharmaceutical ingredients (APIs) for clinical trials.

    Dated: May 16, 2016.
Louis J. Milione,
Deputy Assistant Administrator.
[FR Doc. 2016-11939 Filed 5-19-16; 8:45 am]
 BILLING CODE 4410-09-P